175 related articles for article (PubMed ID: 25266877)
1. Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status.
Fong P; Meng LR
Med Sci Monit Basic Res; 2014 Sep; 20():146-52. PubMed ID: 25266877
[TBL] [Abstract][Full Text] [Related]
2. EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells.
Li T; Yang Y; Li X; Xu C; Meng L
Mol Cell Biochem; 2012 Feb; 361(1-2):19-29. PubMed ID: 21952748
[TBL] [Abstract][Full Text] [Related]
3. [Effect of signal transduction inhibitors on human endometrial carcinoma cells with differential PTEN gene expression].
Xiao L; Yang YB; Shen HM; Xu CF; Wang XY; Li XM
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):681-5. PubMed ID: 20079181
[TBL] [Abstract][Full Text] [Related]
4. The expression of mammalian target of rapamycin in Ishikawa and HEC-1A cells.
Li X; Xiao L; Yang Y; Shen H; Zeng H; Wang Z
J Huazhong Univ Sci Technolog Med Sci; 2008 Jun; 28(3):340-2. PubMed ID: 18563337
[TBL] [Abstract][Full Text] [Related]
5. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
Korets SB; Musa F; Curtin J; Blank SV; Schneider RJ
Gynecol Oncol; 2014 Feb; 132(2):468-73. PubMed ID: 24316308
[TBL] [Abstract][Full Text] [Related]
6. Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice.
Bajwa P; Nielsen S; Lombard JM; Rassam L; Nahar P; Rueda BR; Wilkinson JE; Miller RA; Tanwar PS
Oncotarget; 2017 Jan; 8(5):7265-7275. PubMed ID: 27980219
[TBL] [Abstract][Full Text] [Related]
7. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
Cheng H; Liu P; Zhang F; Xu E; Symonds L; Ohlson CE; Bronson RT; Maira SM; Di Tomaso E; Li J; Myers AP; Cantley LC; Mills GB; Zhao JJ
Cancer Res; 2014 Jan; 74(1):15-23. PubMed ID: 24322983
[TBL] [Abstract][Full Text] [Related]
8. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
9. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
[TBL] [Abstract][Full Text] [Related]
10. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells.
Zhou C; Gehrig PA; Whang YE; Boggess JF
Mol Cancer Ther; 2003 Aug; 2(8):789-95. PubMed ID: 12939469
[TBL] [Abstract][Full Text] [Related]
12. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
13. Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy.
Xiao L; Yang YB; Li XM; Xu CF; Li T; Wang XY
J Cancer Res Clin Oncol; 2010 Jul; 136(7):1089-99. PubMed ID: 20087603
[TBL] [Abstract][Full Text] [Related]
14. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
Seront E; Pinto A; Bouzin C; Bertrand L; Machiels JP; Feron O
Br J Cancer; 2013 Sep; 109(6):1586-92. PubMed ID: 23989949
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
[TBL] [Abstract][Full Text] [Related]
17. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
18. Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.
Mohankumar K; Li X; Sridharan S; Karki K; Safe S
Gynecol Oncol; 2019 Jul; 154(1):218-227. PubMed ID: 31053403
[TBL] [Abstract][Full Text] [Related]
19. Metformin Enhances Nomegestrol Acetate Suppressing Growth of Endometrial Cancer Cells and May Correlate to Downregulating mTOR Activity In Vitro and In Vivo.
Cao C; Zhou JY; Xie SW; Guo XJ; Li GT; Gong YJ; Yang WJ; Li Z; Zhong RH; Shao HH; Zhu Y
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284427
[TBL] [Abstract][Full Text] [Related]
20. Growth and activation of PI-3K/PKB and Akt by stromal cell-derived factor 1alpha in endometrial carcinoma cells with expression of suppressor endoprotein PTEN.
Li XP; Zhao D; Gao M; Zhao C; Wang JL; Wei LH
Chin Med J (Engl); 2006 Mar; 119(5):378-83. PubMed ID: 16542580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
